Parkinson’s disease (PD) is the most common movement disorder and is characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). Dominantly inherited missense mutations in the leucine-rich repeat kinase 2 (Lrrk2) gene are the most common cause of both familial and sporadic PD, highlighting the importance of LRRK2 in PD pathogenesis (Paisán-Ruíz et al., 2004; Shen, 2004; Zimprich et al., 2004; Gilks et al., 2005; Lesage et al., 2007; Kluss et al., 2019; Shu et al., 2019; Mata et al., 2005a; Mata et al., 2005b; Zabetian et al., 2005; Hatano et al., 2014; Takanashi et al., 2018; Nichols et al., 2005; Di Fonzo et al., 2005; Hernandez et al., 2005; Kachergus et al., 2005). LRRK2 is a large protein of 2527 amino acid residues containing multiple functional domains, including several leucine-rich repeats (LRRs), a GTPase-like domain of Ras-of-complex (Roc), a C-terminal of Roc (COR) domain, and a serine/threonine MAPKKK-like kinase domain. LRRK1, a homolog of LRRK2, belongs to the evolutionarily conserved Roco protein family and contains similar LRRs, Roc, COR, and kinase domains (Bosgraaf and Van Haastert, 2003; Marín, 2006; Marín, 2008). LRRK proteins are broadly expressed, with LRRK2 being most abundant in the kidney (Biskup et al., 2007). While most PD mutations are found in LRRK2, rare variants in the Roc, COR, and kinase domains of LRRK1 have been reported and may be associated with PD (Schulte et al., 2014). Furthermore, the Roc-COR domain of LRRK2 forms dimers and exhibits conventional Ras-like GTPase properties, and the R1441/C/G/H and I1371V mutations destabilize dimer formation and decrease GTPase activity (Deng et al., 2008; Mills et al., 2018). Recent high-resolution cryoEM structural studies of full-length LRRK2 demonstrated its existence as dimers and pathogenic mutations such as R1441/C/G/H and Y1699I at the Roc-COR interface, whereas the G2910S mutant is structurally similar to the wild-type LRRK2 (Myasnikov et al., 2021).

Previous genetic studies demonstrated that LRRK2 plays essential roles in the autophagy-lysosomal pathway (Tong et al., 2010; Tong et al., 2012; Herzig et al., 2011; Tian et al., 2021). Consistent with high levels of LRRK2 expression in kidneys, Lrrk2^-/- mice develop age-dependent phenotypes in the kidney, including autophagy-lysosomal impairments and increases in α-synuclein, apoptosis, and inflammatory responses (Tong et al., 2010; Tong et al., 2012; Tong and Shen, 2012). It has also been reported that LRRK2 is important for maintaining lung homeostasis, and Lrrk2 deficiency results in impaired autophagy in alveolar type II epithelial cells (Tian et al., 2021). It was proposed that the lack of brain phenotypes in Lrrk2^-/- mice might be due to the presence of LRRK1, which could compensate functionally in the absence of LRRK2 (Tong et al., 2010; Tong et al., 2012). Indeed, Lrrk double knockout (DKO) mice develop an age-dependent, progressive loss of DA neurons in the SNpc, beginning at 14 months of age (Giaime et al., 2017). However, Lrrk DKO mice also exhibit lower body weight and earlier mortality, raising the possibility that DA neurodegeneration in aged Lrrk germline DKO mice may be secondary to poor health.

In this study, we investigate whether LRRK2 and its functional homolog LRRK1 play an essential, intrinsic role in DA neurons through the development of DA neuron-specific Lrrk conditional DKO (cDKO) mice using the Slc6a3-Cre knockin (KI) allele, in which Cre recombinase is expressed under the control of the endogenous promoter of the dopamine transporter gene Slc6a3. We first generated and confirmed floxed Lrrk1 and Lrrk2 mice, and then crossed them with the CMV-Cre deleter to create germline deletions of the floxed Lrrk1 and Lrrk2 alleles, followed by northern and western analyses to confirm the absence of Lrrk1 and Lrrk2 mRNAs, as well as LRRK1 and LRRK2 proteins in the respective homozygous deleted mutant mice. We also crossed a GFP reporter mouse with Slc6a3-Cre KI mice and confirmed that Cre-mediated recombination occurs in most, if not all, DA neurons in the SNpc and is restricted to DA neurons. We then crossed these thoroughly validated floxed Lrrk1 and Lrrk2 mice with Slc6a3-Cre KI mice to generate DA neuron-restricted Lrrk cDKO mice and further confirmed the reduction of LRRK1 and LRRK2 in dissected ventral midbrains of Lrrk cDKO mice. While DA neuron-restricted Lrrk cDKO mice of both sexes exhibit normal mortality and body weight, they develop age-dependent loss of DA neurons in the SNpc, as demonstrated by the progressive reduction of TH+ DA neurons or NeuN+ neurons in the SNpc of cDKO mice at the ages of 20 and 24 months but not at 15 months. Moreover, DA neurodegeneration is accompanied with increases in apoptotic DA neurons and elevated microgliosis in the SNpc as well as decreases in DA terminals in the striatum, and is preceded by impaired motor coordination. Interestingly, quantitative electron microscopy (EM) analysis showed a similar number of electron-dense vacuoles in SNpc neurons of Lrrk cDKO mice relative to controls, in contrast to age-dependent increases in vacuoles in SNpc neurons of Lrrk germline DKO mice (Giaime et al., 2017; Huang et al., 2022). These findings provide the unequivocal evidence for the importance of LRRK in DA neurons and raise the possibility that LRRK2 mutations may impair this crucial physiological function, leading to DA neurodegeneration in PD.

LRRK2 mutations are linked to familial PD and are also associated with sporadic PD with the G2019S mutation being the most common but exhibiting lower penetrance and higher age of onset (e.g., 74% at age 79) (Healy et al., 2008). Despite the importance of LRRK2 in PD pathogenesis, whether LRRK2 mutations cause DA neurodegeneration via a loss- or gain-of-function mechanism remains unresolved, even though the distinction between these two pathogenic mechanisms is critical for directing LRRK2-based PD therapeutic development. Neither Lrrk2-deficient mice nor Lrrk2 R1441C and G2019S KI mice develop dopaminergic neurodegeneration (Tong et al., 2010; Tong et al., 2009; Yue et al., 2015). It was proposed that the lack of brain phenotypes in Lrrk2-null mice might be due to the presence of LRRK1 (Tong et al., 2010; Tong et al., 2012), which is broadly expressed in the brain including the midbrain (https://www.proteinatlas.org/ENSG00000154237-LRRK1/brain). Indeed, germline deletions of Lrrk2 and Lrrk1 result in an age-dependent loss of DA neurons and increases in apoptosis and microgliosis in the SNpc of Lrrk DKO mice (Giaime et al., 2017; Huang et al., 2022). However, the pleiotropic roles of LRRK1 and LRRK2 in the kidney (Tong et al., 2010; Tong et al., 2012; Tong and Shen, 2012), lung (Tian et al., 2021), and bone (Xing et al., 2013; Guo et al., 2017), and the observed earlier mortality and lower body weight in Lrrk DKO mice raised the possibility that DA neurodegeneration in Lrrk DKO mice may be due to poor health.

To address this question, we generated floxed Lrrk1 and Lrrk2 mice (Figure 1Figure 1—figure supplements 1–8) and DA neuron-specific Lrrk cDKO mice using the Slc6a3-Cre KI allele (Bäckman et al., 2006) to delete floxed Lrrk1 and Lrrk2 regions selectively in DA neurons (Figure 2). Using a GFP reporter line, we found that Slc6a3-Cre drives Cre-mediated recombination in almost all DA neurons in the SNpc. Unlike germline DKO mice (Giaime et al., 2017), DA neuron-specific Lrrk cDKO mice exhibit normal body weight and mortality during mouse lifespan. Importantly, Lrrk cDKO mice develop an age-dependent, progressive DA neurodegeneration, as evidenced by the normal number of DA neurons at the age of 15 months and the progressive reduction of DA neurons in the SNpc at the ages of 20 and 24 months (Figure 3), accompanied with increases in apoptotic DA neurons in the SNpc (Figure 4) and decreases in DA terminals in the striatum (Figure 5), whereas the number of noradrenergic neurons in the LC is unchanged, consistent with the lack of Cre-mediated recombination in the LC by Slc6a3-Cre (Figure 6). Moreover, Lrrk cDKO mice exhibit impaired performance in a narrow beam walk, a behavioral paradigm sensitive to altered motor coordination (Figure 9). Furthermore, microgliosis is elevated in the SNpc of Lrrk cDKO mice, even though LRRK expression in microglia is unaffected in these mice, suggesting a cell-extrinsic microglial response to pathophysiological changes in DA neurons (Figure 8). The molecular mechanism by which LRRK supports cell-autonomous DA neuron survival is unknown. Single-cell RNA sequencing of dissected ventral midbrains may permit identification of genes and pathways that are selectively altered in DA neurons of Lrrk cDKO mice before and after the onset of DA neurodegeneration.

Interestingly, quantitative EM analysis showed similar numbers of electron-dense vacuoles in the SNpc of Lrrk cDKO and control mice at 25 months of age (Figure 7), in contrast to age-dependent increases in vacuoles in the SNpc of Lrrk DKO mice (Giaime et al., 2017; Huang et al., 2022), suggesting non-DA neurons (e.g., microglia), in which LRRK expression is unaffected in DA neuron-specific Lrrk cDKO mice but is absent in germline DKO mice, may contribute to this phenotypic difference. Development of microglia- and/or astrocyte-specific Lrrk cDKO mice would permit further dissection of cell-autonomous and non-cell-autonomous roles of LRRK in DA neuron survival and determine whether glial LRRK plays a more important role in the regulation of the autophagy-lysosomal pathway and protein turnover. It would also be interesting to test whether reducing LRRK expression or function affects accumulation and aggregation of human mutant α-synuclein and tau in the aging brain, as both Lewy bodies and tauopathies are associated with PD patients carrying LRRK2 mutations (Zimprich et al., 2004).

The toxic gain-of-function pathogenic mechanism was initially proposed based on in vitro kinase assays using recombinant mutant LRRK2, which showed that R1441C and G2019S resulted in increases in autophosphorylation and phosphorylation of a generic substrate (West et al., 2005). Subsequent biochemical studies further reported that LRRK2 mutations (e.g., R1441C/G, G2019S) enhanced kinase activity, leading to elevated levels of pSer1292-LRRK2 (Sheng et al., 2012) as well as pT73-Rab10 and pS106-Rab12 (Steger et al., 2016). While these biochemical changes are excellent biomarkers of LRRK2 mutations, there is no experimental evidence showing that increased phosphorylation of LRRK2 substrates drives DA neurodegeneration.

The loss-of-function pathogenic mechanism was prompted by mouse knockout findings showing that germline inactivation of the Lrrk genes results in age-dependent loss of DA neurons in the SNpc and DA terminals in the striatum (Giaime et al., 2017; Huang et al., 2022). The current study demonstrated a cell-intrinsic role of LRRK in support of DA neuron survival in the SNpc of the aging brain, providing an unequivocal genetic evidence of an essential, cell-autonomous requirement of LRRK in DA neurons. While most transgenic mice overexpressing mutant LRRK2 did not produce neurodegeneration or DA neuron loss (Li et al., 2009; Lin et al., 2009; Li et al., 2010; Melrose et al., 2010; Daher et al., 2012; Tsika et al., 2014; Liu et al., 2015; Mikhail et al., 2015; Xiong et al., 2017), two studies reported that overexpression of LRRK2 G2019S but not R1441C resulted in DA neurodegeneration (Ramonet et al., 2011; Xiong et al., 2018). These transgenic mouse results are intriguing as R1441C is a more potent causative mutation (highly penetrant, in a critical amino acid residue that harbors three distinct PD mutations), whereas G2019S is known to be a weaker mutation with a lower penetrance and an older age of disease onset.

It remains possible that the relevant physiological role of LRRK in the protection of DA neuron survival during aging may be irrelevant to how LRRK2 mutations cause DA neurodegeneration and PD. Two reports of genomic database analysis suggested that loss-of-function Lrrk2 and Lrrk1 variants are not associated with PD (Whiffin et al., 2020; Blauwendraat et al., 2018), which were sometimes taken as conclusive evidence for LRRK2 mutations not being loss of function. One study was a predictive analysis using several available sequencing databases (141,456 individuals sequenced in the Genome Aggregation Database, 49,960 exome-sequenced individuals from the UK Biobank, and more than 4 million participants in the 23andMe genotyped dataset), and the authors cautiously stated that heterozygous predicted loss-of-function variants are not strongly associated with PD (Whiffin et al., 2020). Another study analyzed next-generation sequencing data from 11,095 PD patients and 12,615 controls, and found that Lrrk1 loss-of-function variants were identified in 0.205% PD cases and 0.139% of controls, whereas Lrrk2 loss-of-function variants were found in 0.117% of PD cases and 0.087% of controls (Blauwendraat et al., 2018). In contrast to linkage studies of large pedigrees with mutations segregating completely with the disease but being absent among control populations, these genomic database analysis studies are considerably weaker with the results suggestive but highly inconclusive. For example, while the occurrence of these loss-of-function variants among PD patients is not statistically different from those among control populations, a larger sample size may change this outcome. Furthermore, such sequencing data tend to be from highly heterogeneous populations, contributing to further complexity. Moreover, it is quite possible that haploinsufficiency or heterozygous complete loss-of-function mutations are not sufficient to cause the disease; rather a dominant negative mechanism, coupled with loss of function missense mutations, may be at play, reducing overall protein function further, especially if dimers are the functional entities. Therefore, these studies are interesting but inconclusive as to whether loss-of-function mutations in LRRK2 or LRRK1 cause or do not cause PD.

Genetically, it is well known that missense mutations may gain a toxic function or may cause a partial loss of function in cis and a dominant negative inhibition of wild-type protein in trans, further reducing its function. Missense mutations in the PSEN genes linked to familial Alzheimer’s disease are good examples of such a loss-of-function coupled with a dominant negative mechanism (Shen and Kelleher, 2007; Heilig et al., 2010; Heilig et al., 2013; Zhou et al., 2017; Watanabe and Shen, 2017; Sun et al., 2017; Kelleher and Shen, 2017). While PD-linked Lrrk2 mutations are mostly dominantly inherited missense mutations, though homozygous R1441H carriers have been reported (Takanashi et al., 2018), variants in LRRK1 have also been reported with inconclusive pathogenicity (Schulte et al., 2014; Haugarvoll et al., 2007). The notion that mutant LRRK2 may act in a dominant negative manner to inhibit the activity of wild-type LRRK2 is supported by structural and functional studies of LRRK2 as homodimers or heterodimers with LRRK1 (Deng et al., 2008; Myasnikov et al., 2021; Zhang et al., 2019; Greggio et al., 2008; Sen et al., 2009; Jorgensen et al., 2009; Dachsel et al., 2010). Furthermore, LRRK2 G2385R variant, a risk factor of PD (Farrer et al., 2007; Kim et al., 2010; An et al., 2008; Xie et al., 2014), has been reported as a partial loss-of-function mutation (Rudenko et al., 2012; Carrion et al., 2017). Future studies are needed to reconcile the biochemical findings of elevated kinase activity by LRRK2 mutations and the genetic findings of an essential physiological role of LRRK in DA neuron survival, and to determine whether LRRK2 mutations impair this relevant physiological function in protecting DA neurons while increasing kinase activity.

All data generated or analysed during this study are included in the manuscript and supporting files; source data files have been provided for key findings shown in Figures 1, 3, 4, 8, and 9.

1. 1. An X-K
   2. Peng R
   3. Li T
   4. Burgunder J-M
   5. Wu Y
   6. Chen W-J
   7. Zhang J-H
   8. Wang Y-C
   9. Xu Y-M
   10. Gou Y-R
   11. Yuan G-G
   12. Zhang Z-J

   (2008) LRRK2 Gly2385Arg variant is a risk factor of Parkinson’s disease among Han-Chinese from mainland China

   European Journal of Neurology 15:301–305.

   https://doi.org/10.1111/j.1468-1331.2007.02052.x

   • PubMed
   • Google Scholar
2. 1. Bäckman CM
   2. Malik N
   3. Zhang Y
   4. Shan L
   5. Grinberg A
   6. Hoffer BJ
   7. Westphal H
   8. Tomac AC

   (2006) Characterization of a mouse strain expressing Cre recombinase from the 3’ untranslated region of the dopamine transporter locus

   Genesis 44:383–390.

   https://doi.org/10.1002/dvg.20228

   • PubMed
   • Google Scholar
3. 1. Biskup S
   2. Moore DJ
   3. Rea A
   4. Lorenz-Deperieux B
   5. Coombes CE
   6. Dawson VL
   7. Dawson TM
   8. West AB

   (2007) Dynamic and redundant regulation of LRRK2 and LRRK1 expression

   BMC Neuroscience 8:102.

   https://doi.org/10.1186/1471-2202-8-102

   • PubMed
   • Google Scholar
4. 1. Blauwendraat C
   2. Reed X
   3. Kia DA
   4. Gan-Or Z
   5. Lesage S
   6. Pihlstrøm L
   7. Guerreiro R
   8. Gibbs JR
   9. Sabir M
   10. Ahmed S
   11. Ding J
   12. Alcalay RN
   13. Hassin-Baer S
   14. Pittman AM
   15. Brooks J
   16. Edsall C
   17. Hernandez DG
   18. Chung SJ
   19. Goldwurm S
   20. Toft M
   21. Schulte C
   22. Bras J
   23. Wood NW
   24. Brice A
   25. Morris HR
   26. Scholz SW
   27. Nalls MA
   28. Singleton AB
   29. Cookson MR
   30. COURAGE-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson’s Disease) Consortium, the French Parkinson’s Disease Consortium, and the International Parkinson’s Disease Genomics Consortium (IPDGC)

   (2018) Frequency of loss of function variants in LRRK2 in Parkinson disease

   JAMA Neurology 75:1416–1422.

   https://doi.org/10.1001/jamaneurol.2018.1885

   • PubMed
   • Google Scholar
5. 1. Bosgraaf L
   2. Van Haastert PJM

   (2003) Roc, a Ras/GTPase domain in complex proteins

   Biochimica et Biophysica Acta 1643:5–10.

   https://doi.org/10.1016/j.bbamcr.2003.08.008

   • PubMed
   • Google Scholar
6. 1. Carrion MDP
   2. Marsicano S
   3. Daniele F
   4. Marte A
   5. Pischedda F
   6. Di Cairano E
   7. Piovesana E
   8. von Zweydorf F
   9. Kremmer E
   10. Gloeckner CJ
   11. Onofri F
   12. Perego C
   13. Piccoli G

   (2017) The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions

   Scientific Reports 7:5377.

   https://doi.org/10.1038/s41598-017-05760-9

   • PubMed
   • Google Scholar
7. 1. Dachsel JC
   2. Nishioka K
   3. Vilariño-Güell C
   4. Lincoln SJ
   5. Soto-Ortolaza AI
   6. Kachergus J
   7. Hinkle KM
   8. Heckman MG
   9. Jasinska-Myga B
   10. Taylor JP
   11. Dickson DW
   12. Gibson RA
   13. Hentati F
   14. Ross OA
   15. Farrer MJ

   (2010) Heterodimerization of Lrrk1-LRRK2: Implications for LRRK2-associated Parkinson disease

   Mechanisms of Ageing and Development 131:210–214.

   https://doi.org/10.1016/j.mad.2010.01.009

   • PubMed
   • Google Scholar
8. 1. Daher JPL
   2. Pletnikova O
   3. Biskup S
   4. Musso A
   5. Gellhaar S
   6. Galter D
   7. Troncoso JC
   8. Lee MK
   9. Dawson TM
   10. Dawson VL
   11. Moore DJ

   (2012) Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2

   Human Molecular Genetics 21:2420–2431.

   https://doi.org/10.1093/hmg/dds057

   • PubMed
   • Google Scholar
9. 1. Deng J
   2. Lewis PA
   3. Greggio E
   4. Sluch E
   5. Beilina A
   6. Cookson MR

   (2008) Structure of the ROC domain from the Parkinson’s disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase

   PNAS 105:1499–1504.

   https://doi.org/10.1073/pnas.0709098105

   • PubMed
   • Google Scholar
10. 1. Di Fonzo A
    2. Rohé CF
    3. Ferreira J
    4. Chien HF
    5. Vacca L
    6. Stocchi F
    7. Guedes L
    8. Fabrizio E
    9. Manfredi M
    10. Vanacore N
    11. Goldwurm S
    12. Breedveld G
    13. Sampaio C
    14. Meco G
    15. Barbosa E
    16. Oostra BA
    17. Bonifati V
    18. Italian Parkinson Genetics Network

    (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease

    Lancet 365:412–415.

    https://doi.org/10.1016/S0140-6736(05)17829-5

    • PubMed
    • Google Scholar
11. 1. Farrer MJ
    2. Stone JT
    3. Lin C-H
    4. Dächsel JC
    5. Hulihan MM
    6. Haugarvoll K
    7. Ross OA
    8. Wu R-M

    (2007) Lrrk2 G2385R is an ancestral risk factor for Parkinson’s disease in Asia

    Parkinsonism & Related Disorders 13:89–92.

    https://doi.org/10.1016/j.parkreldis.2006.12.001

    • PubMed
    • Google Scholar
12. 1. Giaime E
    2. Tong Y
    3. Wagner LK
    4. Yuan Y
    5. Huang G
    6. Shen J

    (2017) Age-dependent dopaminergic neurodegeneration and impairment of the autophagy-lysosomal pathway in LRRK-Deficient Mice

    Neuron 96:796–807.

    https://doi.org/10.1016/j.neuron.2017.09.036

    • PubMed
    • Google Scholar
13. 1. Gilks WP
    2. Abou-Sleiman PM
    3. Gandhi S
    4. Jain S
    5. Singleton A
    6. Lees AJ
    7. Shaw K
    8. Bhatia KP
    9. Bonifati V
    10. Quinn NP
    11. Lynch J
    12. Healy DG
    13. Holton JL
    14. Revesz T
    15. Wood NW

    (2005) A common LRRK2 mutation in idiopathic Parkinson’s disease

    Lancet 365:415–416.

    https://doi.org/10.1016/S0140-6736(05)17830-1

    • PubMed
    • Google Scholar
14. 1. Greggio E
    2. Zambrano I
    3. Kaganovich A
    4. Beilina A
    5. Taymans J-M
    6. Daniëls V
    7. Lewis P
    8. Jain S
    9. Ding J
    10. Syed A
    11. Thomas KJ
    12. Baekelandt V
    13. Cookson MR

    (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation

    The Journal of Biological Chemistry 283:16906–16914.

    https://doi.org/10.1074/jbc.M708718200

    • PubMed
    • Google Scholar
15. 1. Guo L
    2. Girisha KM
    3. Iida A
    4. Hebbar M
    5. Shukla A
    6. Shah H
    7. Nishimura G
    8. Matsumoto N
    9. Nismath S
    10. Miyake N
    11. Ikegawa S

    (2017) Identification of a novel LRRK1 mutation in a family with osteosclerotic metaphyseal dysplasia

    Journal of Human Genetics 62:437–441.

    https://doi.org/10.1038/jhg.2016.136

    • PubMed
    • Google Scholar
16. 1. Hatano T
    2. Funayama M
    3. Kubo SI
    4. Mata IF
    5. Oji Y
    6. Mori A

    (2014) Identification of a Japanese family with LRRK2

    Neurobiology of Aging 35:025.

    https://doi.org/10.1016/j.neurobiolaging.2014.05.025

    • Google Scholar
17. 1. Haugarvoll K
    2. Toft M
    3. Ross OA
    4. White LR
    5. Aasly JO
    6. Farrer MJ

    (2007) Variants in the LRRK1 gene and susceptibility to Parkinson’s disease in Norway

    Neuroscience Letters 416:299–301.

    https://doi.org/10.1016/j.neulet.2007.02.020

    • PubMed
    • Google Scholar
18. 1. Healy DG
    2. Falchi M
    3. O’Sullivan SS
    4. Bonifati V
    5. Durr A
    6. Bressman S
    7. Brice A
    8. Aasly J
    9. Zabetian CP
    10. Goldwurm S
    11. Ferreira JJ
    12. Tolosa E
    13. Kay DM
    14. Klein C
    15. Williams DR
    16. Marras C
    17. Lang AE
    18. Wszolek ZK
    19. Berciano J
    20. Schapira AHV
    21. Lynch T
    22. Bhatia KP
    23. Gasser T
    24. Lees AJ
    25. Wood NW
    26. International LRRK2 Consortium

    (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study

    The Lancet. Neurology 7:583–590.

    https://doi.org/10.1016/S1474-4422(08)70117-0

    • PubMed
    • Google Scholar
19. 1. Heilig EA
    2. Xia W
    3. Shen J
    4. Kelleher RJ

    (2010) A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes A nearly complete loss of gamma-secretase activity

    The Journal of Biological Chemistry 285:22350–22359.

    https://doi.org/10.1074/jbc.M110.116962

    • PubMed
    • Google Scholar
20. 1. Heilig EA
    2. Gutti U
    3. Tai T
    4. Shen J
    5. Kelleher RJ

    (2013) Trans-dominant negative effects of pathogenic PSEN1 mutations on γ-secretase activity and Aβ production

    The Journal of Neuroscience 33:11606–11617.

    https://doi.org/10.1523/JNEUROSCI.0954-13.2013

    • PubMed
    • Google Scholar
21. 1. Hernandez DG
    2. Paisán-Ruíz C
    3. McInerney-Leo A
    4. Jain S
    5. Meyer-Lindenberg A
    6. Evans EW
    7. Berman KF
    8. Johnson J
    9. Auburger G
    10. Schäffer AA
    11. Lopez GJ
    12. Nussbaum RL
    13. Singleton AB

    (2005) Clinical and positron emission tomography of Parkinson’s disease caused by LRRK2

    Annals of Neurology 57:453–456.

    https://doi.org/10.1002/ana.20401

    • PubMed
    • Google Scholar
22. 1. Herzig MC
    2. Kolly C
    3. Persohn E
    4. Theil D
    5. Schweizer T
    6. Hafner T
    7. Stemmelen C
    8. Troxler TJ
    9. Schmid P
    10. Danner S
    11. Schnell CR
    12. Mueller M
    13. Kinzel B
    14. Grevot A
    15. Bolognani F
    16. Stirn M
    17. Kuhn RR
    18. Kaupmann K
    19. van der Putten PH
    20. Rovelli G
    21. Shimshek DR

    (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice

    Human Molecular Genetics 20:4209–4223.

    https://doi.org/10.1093/hmg/ddr348

    • PubMed
    • Google Scholar
23. 1. Huang G
    2. Bloodgood DW
    3. Kang J
    4. Shahapal A
    5. Chen P
    6. Kaganovsky K
    7. Kim J-I
    8. Ding JB
    9. Shen J

    (2022) Motor impairments and dopaminergic defects caused by loss of leucine-rich repeat kinase function in mice

    The Journal of Neuroscience 42:4755–4765.

    https://doi.org/10.1523/JNEUROSCI.0140-22.2022

    • PubMed
    • Google Scholar
24. 1. Jorgensen ND
    2. Peng Y
    3. Ho CC-Y
    4. Rideout HJ
    5. Petrey D
    6. Liu P
    7. Dauer WT

    (2009) The WD40 domain is required for LRRK2 neurotoxicity

    PLOS ONE 4:e8463.

    https://doi.org/10.1371/journal.pone.0008463

    • PubMed
    • Google Scholar
25. 1. Kachergus J
    2. Mata IF
    3. Hulihan M
    4. Taylor JP
    5. Lincoln S
    6. Aasly J
    7. Gibson JM
    8. Ross OA
    9. Lynch T
    10. Wiley J
    11. Payami H
    12. Nutt J
    13. Maraganore DM
    14. Czyzewski K
    15. Styczynska M
    16. Wszolek ZK
    17. Farrer MJ
    18. Toft M

    (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations

    American Journal of Human Genetics 76:672–680.

    https://doi.org/10.1086/429256

    • PubMed
    • Google Scholar
26. 1. Kang J
    2. Watanabe H
    3. Shen J

    (2021) Protocols for assessing neurodegenerative phenotypes in Alzheimer’s mouse models

    STAR Protocols 2:100654.

    https://doi.org/10.1016/j.xpro.2021.100654

    • PubMed
    • Google Scholar
27. 1. Kelleher RJ
    2. Shen J

    (2017) Presenilin-1 mutations and Alzheimer’s disease

    PNAS 114:629–631.

    https://doi.org/10.1073/pnas.1619574114

    • PubMed
    • Google Scholar
28. 1. Kim J-M
    2. Lee J-Y
    3. Kim HJ
    4. Kim JS
    5. Shin E-S
    6. Cho J-H
    7. Park SS
    8. Jeon BS

    (2010) The LRRK2 G2385R variant is a risk factor for sporadic Parkinson’s disease in the Korean population

    Parkinsonism & Related Disorders 16:85–88.

    https://doi.org/10.1016/j.parkreldis.2009.10.004

    • Google Scholar
29. 1. Kluss JH
    2. Mamais A
    3. Cookson MR

    (2019) LRRK2 links genetic and sporadic Parkinson’s disease

    Biochemical Society Transactions 47:651–661.

    https://doi.org/10.1042/BST20180462

    • PubMed
    • Google Scholar
30. 1. Lesage S
    2. Janin S
    3. Lohmann E
    4. Leutenegger AL
    5. Leclere L
    6. Viallet F
    7. Pollak P
    8. Durif F
    9. Thobois S
    10. Layet V
    11. Vidailhet M
    12. Agid Y
    13. Dürr A
    14. Brice A
    15. Bonnet AM
    16. Borg M
    17. Broussolle E
    18. Damier P
    19. Destée A
    20. Martinez M
    21. Penet C
    22. Rasco O
    23. Tison F
    24. Tranchan C
    25. Vérin M

    (2007) LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans

    Archives of Neurology 64:425–430.

    https://doi.org/10.1001/archneur.64.3.425

    • PubMed
    • Google Scholar
31. 1. Li Y
    2. Liu W
    3. Oo TF
    4. Wang L
    5. Tang Y
    6. Jackson-Lewis V
    7. Zhou C
    8. Geghman K
    9. Bogdanov M
    10. Przedborski S
    11. Beal MF
    12. Burke RE
    13. Li C

    (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease

    Nature Neuroscience 12:826–828.

    https://doi.org/10.1038/nn.2349

    • PubMed
    • Google Scholar
32. 1. Li X
    2. Patel JC
    3. Wang J
    4. Avshalumov MV
    5. Nicholson C
    6. Buxbaum JD
    7. Elder GA
    8. Rice ME
    9. Yue Z

    (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease mutation G2019S

    The Journal of Neuroscience 30:1788–1797.

    https://doi.org/10.1523/JNEUROSCI.5604-09.2010

    • PubMed
    • Google Scholar
33. 1. Lin X
    2. Parisiadou L
    3. Gu X-L
    4. Wang L
    5. Shim H
    6. Sun L
    7. Xie C
    8. Long C-X
    9. Yang W-J
    10. Ding J
    11. Chen ZZ
    12. Gallant PE
    13. Tao-Cheng J-H
    14. Rudow G
    15. Troncoso JC
    16. Liu Z
    17. Li Z
    18. Cai H

    (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein

    Neuron 64:807–827.

    https://doi.org/10.1016/j.neuron.2009.11.006

    • PubMed
    • Google Scholar
34. 1. Liu G
    2. Sgobio C
    3. Gu X
    4. Sun L
    5. Lin X
    6. Yu J
    7. Parisiadou L
    8. Xie C
    9. Sastry N
    10. Ding J
    11. Lohr KM
    12. Miller GW
    13. Mateo Y
    14. Lovinger DM
    15. Cai H

    (2015) Selective expression of Parkinson’s disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression

    Human Molecular Genetics 24:5299–5312.

    https://doi.org/10.1093/hmg/ddv249

    • PubMed
    • Google Scholar
35. 1. Madisen L
    2. Zwingman TA
    3. Sunkin SM
    4. Oh SW
    5. Zariwala HA
    6. Gu H
    7. Ng LL
    8. Palmiter RD
    9. Hawrylycz MJ
    10. Jones AR
    11. Lein ES
    12. Zeng H

    (2010) A robust and high-throughput Cre reporting and characterization system for the whole mouse brain

    Nature Neuroscience 13:133–140.

    https://doi.org/10.1038/nn.2467

    • PubMed
    • Google Scholar
36. 1. Marín I

    (2006) The Parkinson disease gene LRRK2: evolutionary and structural insights

    Molecular Biology and Evolution 23:2423–2433.

    https://doi.org/10.1093/molbev/msl114

    • PubMed
    • Google Scholar
37. 1. Marín I

    (2008) Ancient origin of the Parkinson disease gene LRRK2

    Journal of Molecular Evolution 67:41–50.

    https://doi.org/10.1007/s00239-008-9122-4

    • PubMed
    • Google Scholar
38. 1. Mata IF
    2. Kachergus JM
    3. Taylor JP
    4. Lincoln S
    5. Aasly J
    6. Lynch T
    7. Hulihan MM
    8. Cobb SA
    9. Wu R-M
    10. Lu C-S
    11. Lahoz C
    12. Wszolek ZK
    13. Farrer MJ

    (2005a) LRRK2 pathogenic substitutions in Parkinson’s disease

    Neurogenetics 6:171–177.

    https://doi.org/10.1007/s10048-005-0005-1

    • PubMed
    • Google Scholar
39. 1. Mata IF
    2. Taylor JP
    3. Kachergus J
    4. Hulihan M
    5. Huerta C
    6. Lahoz C
    7. Blazquez M
    8. Guisasola LM
    9. Salvador C
    10. Ribacoba R
    11. Martinez C
    12. Farrer M
    13. Alvarez V

    (2005b) LRRK2 R1441G in Spanish patients with Parkinson’s disease

    Neuroscience Letters 382:309–311.

    https://doi.org/10.1016/j.neulet.2005.03.033

    • PubMed
    • Google Scholar
40. 1. Melrose HL
    2. Dächsel JC
    3. Behrouz B
    4. Lincoln SJ
    5. Yue M
    6. Hinkle KM
    7. Kent CB
    8. Korvatska E
    9. Taylor JP
    10. Witten L
    11. Liang Y-Q
    12. Beevers JE
    13. Boules M
    14. Dugger BN
    15. Serna VA
    16. Gaukhman A
    17. Yu X
    18. Castanedes-Casey M
    19. Braithwaite AT
    20. Ogholikhan S
    21. Yu N
    22. Bass D
    23. Tyndall G
    24. Schellenberg GD
    25. Dickson DW
    26. Janus C
    27. Farrer MJ

    (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice

    Neurobiology of Disease 40:503–517.

    https://doi.org/10.1016/j.nbd.2010.07.010

    • PubMed
    • Google Scholar
41. 1. Mikhail F
    2. Calingasan N
    3. Parolari L
    4. Subramanian A
    5. Yang L
    6. Flint Beal M

    (2015) Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau

    Human Molecular Genetics 24:3545–3556.

    https://doi.org/10.1093/hmg/ddv105

    • PubMed
    • Google Scholar
42. 1. Mills RD
    2. Liang L-Y
    3. Lio DS-S
    4. Mok Y-F
    5. Mulhern TD
    6. Cao G
    7. Griffin M
    8. Kenche VB
    9. Culvenor JG
    10. Cheng H-C

    (2018) The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties

    Journal of Neurochemistry 147:409–428.

    https://doi.org/10.1111/jnc.14566

    • PubMed
    • Google Scholar
43. 1. Myasnikov A
    2. Zhu H
    3. Hixson P
    4. Xie B
    5. Yu K
    6. Pitre A
    7. Peng J
    8. Sun J

    (2021) Structural analysis of the full-length human LRRK2

    Cell 184:3519–3527.

    https://doi.org/10.1016/j.cell.2021.05.004

    • PubMed
    • Google Scholar
44. 1. Nelson EL
    2. Liang CL
    3. Sinton CM
    4. German DC

    (1996) Midbrain dopaminergic neurons in the mouse: computer-assisted mapping

    The Journal of Comparative Neurology 369:361–371.

    https://doi.org/10.1002/(SICI)1096-9861(19960603)369:3<361::AID-CNE3>3.0.CO;2-3

    • PubMed
    • Google Scholar
45. 1. Nichols WC
    2. Pankratz N
    3. Hernandez D
    4. Paisán-Ruíz C
    5. Jain S
    6. Halter CA
    7. Michaels VE
    8. Reed T
    9. Rudolph A
    10. Shults CW
    11. Singleton A
    12. Foroud T
    13. Parkinson Study Group-PROGENI investigators

    (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease

    Lancet 365:410–412.

    https://doi.org/10.1016/S0140-6736(05)17828-3

    • PubMed
    • Google Scholar
46. 1. Paisán-Ruíz C
    2. Jain S
    3. Evans EW
    4. Gilks WP
    5. Simón J
    6. van der Brug M
    7. López de Munain A
    8. Aparicio S
    9. Gil AM
    10. Khan N
    11. Johnson J
    12. Martinez JR
    13. Nicholl D
    14. Martí Carrera I
    15. Pena AS
    16. de Silva R
    17. Lees A
    18. Martí-Massó JF
    19. Pérez-Tur J
    20. Wood NW
    21. Singleton AB

    (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease

    Neuron 44:595–600.

    https://doi.org/10.1016/j.neuron.2004.10.023

    • PubMed
    • Google Scholar
47. 1. Ramonet D
    2. Daher JPL
    3. Lin BM
    4. Stafa K
    5. Kim J
    6. Banerjee R
    7. Westerlund M
    8. Pletnikova O
    9. Glauser L
    10. Yang L
    11. Liu Y
    12. Swing DA
    13. Beal MF
    14. Troncoso JC
    15. McCaffery JM
    16. Jenkins NA
    17. Copeland NG
    18. Galter D
    19. Thomas B
    20. Lee MK
    21. Dawson TM
    22. Dawson VL
    23. Moore DJ

    (2011) Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2

    PLOS ONE 6:e18568.

    https://doi.org/10.1371/journal.pone.0018568

    • PubMed
    • Google Scholar
48. 1. Rodríguez CI
    2. Buchholz F
    3. Galloway J
    4. Sequerra R
    5. Kasper J
    6. Ayala R
    7. Stewart AF
    8. Dymecki SM

    (2000) High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP

    Nature Genetics 25:139–140.

    https://doi.org/10.1038/75973

    • PubMed
    • Google Scholar
49. 1. Rudenko IN
    2. Kaganovich A
    3. Hauser DN
    4. Beylina A
    5. Chia R
    6. Ding J
    7. Maric D
    8. Jaffe H
    9. Cookson MR

    (2012) The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson’s disease is a partial loss-of-function mutation

    The Biochemical Journal 446:99–111.

    https://doi.org/10.1042/BJ20120637

    • PubMed
    • Google Scholar
50. 1. Schindelin J
    2. Arganda-Carreras I
    3. Frise E
    4. Kaynig V
    5. Longair M
    6. Pietzsch T
    7. Preibisch S
    8. Rueden C
    9. Saalfeld S
    10. Schmid B
    11. Tinevez J-Y
    12. White DJ
    13. Hartenstein V
    14. Eliceiri K
    15. Tomancak P
    16. Cardona A

    (2012) Fiji: an open-source platform for biological-image analysis

    Nature Methods 9:676–682.

    https://doi.org/10.1038/nmeth.2019

    • PubMed
    • Google Scholar
51. 1. Schulte EC
    2. Ellwanger DC
    3. Dihanich S
    4. Manzoni C
    5. Stangl K
    6. Schormair B
    7. Graf E
    8. Eck S
    9. Mollenhauer B
    10. Haubenberger D
    11. Pirker W
    12. Zimprich A
    13. Brücke T
    14. Lichtner P
    15. Peters A
    16. Gieger C
    17. Trenkwalder C
    18. Mewes H-W
    19. Meitinger T
    20. Lewis PA
    21. Klünemann HH
    22. Winkelmann J

    (2014) Rare variants in LRRK1 and Parkinson’s disease

    Neurogenetics 15:49–57.

    https://doi.org/10.1007/s10048-013-0383-8

    • PubMed
    • Google Scholar
52. 1. Schwenk F
    2. Baron U
    3. Rajewsky K

    (1995) A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells

    Nucleic Acids Research 23:5080–5081.

    https://doi.org/10.1093/nar/23.24.5080

    • PubMed
    • Google Scholar
53. 1. Sen S
    2. Webber PJ
    3. West AB

    (2009) Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization

    The Journal of Biological Chemistry 284:36346–36356.

    https://doi.org/10.1074/jbc.M109.025437

    • PubMed
    • Google Scholar
54. 1. Shen J

    (2004) Protein kinases linked to the pathogenesis of parkinson’s disease

    Neuron 44:575–577.

    https://doi.org/10.1016/j.neuron.2004.11.008

    • Google Scholar
55. 1. Shen J
    2. Kelleher RJ III

    (2007) The presenilin hypothesis of Alzheimer’s disease: Evidence for a loss-of-function pathogenic mechanism

    PNAS 104:403–409.

    https://doi.org/10.1073/pnas.0608332104

    • Google Scholar
56. 1. Sheng Z
    2. Zhang S
    3. Bustos D
    4. Kleinheinz T
    5. Le Pichon CE
    6. Dominguez SL
    7. Solanoy HO
    8. Drummond J
    9. Zhang X
    10. Ding X
    11. Cai F
    12. Song Q
    13. Li X
    14. Yue Z
    15. van der Brug MP
    16. Burdick DJ
    17. Gunzner-Toste J
    18. Chen H
    19. Liu X
    20. Estrada AA
    21. Sweeney ZK
    22. Scearce-Levie K
    23. Moffat JG
    24. Kirkpatrick DS
    25. Zhu H

    (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations

    Science Translational Medicine 4:164ra161.

    https://doi.org/10.1126/scitranslmed.3004485

    • PubMed
    • Google Scholar
57. 1. Shu L
    2. Zhang Y
    3. Sun Q
    4. Pan H
    5. Tang B

    (2019) A comprehensive analysis of population differences in LRRK2 variant distribution in parkinson’s disease

    Frontiers in Aging Neuroscience 11:13.

    https://doi.org/10.3389/fnagi.2019.00013

    • PubMed
    • Google Scholar
58. 1. Steger M
    2. Tonelli F
    3. Ito G
    4. Davies P
    5. Trost M
    6. Vetter M
    7. Wachter S
    8. Lorentzen E
    9. Duddy G
    10. Wilson S
    11. Baptista MA
    12. Fiske BK
    13. Fell MJ
    14. Morrow JA
    15. Reith AD
    16. Alessi DR
    17. Mann M

    (2016) Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases

    eLife 5:e12813.

    https://doi.org/10.7554/eLife.12813

    • PubMed
    • Google Scholar
59. 1. Sun L
    2. Zhou R
    3. Yang G
    4. Shi Y

    (2017) Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase

    PNAS 114:E476–E485.

    https://doi.org/10.1073/pnas.1618657114

    • PubMed
    • Google Scholar
60. 1. Takanashi M
    2. Funayama M
    3. Matsuura E
    4. Yoshino H
    5. Li Y
    6. Tsuyama S
    7. Takashima H
    8. Nishioka K
    9. Hattori N

    (2018) Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations

    Acta Neuropathologica Communications 6:105.

    https://doi.org/10.1186/s40478-018-0617-y

    • PubMed
    • Google Scholar
61. 1. Tian Y
    2. Lv J
    3. Su Z
    4. Wu T
    5. Li X
    6. Hu X
    7. Zhang J
    8. Wu L

    (2021) LRRK2 plays essential roles in maintaining lung homeostasis and preventing the development of pulmonary fibrosis

    PNAS 118:e2106685118.

    https://doi.org/10.1073/pnas.2106685118

    • PubMed
    • Google Scholar
62. 1. Tong Y
    2. Pisani A
    3. Martella G
    4. Karouani M
    5. Yamaguchi H
    6. Pothos EN
    7. Shen J

    (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice

    PNAS 106:14622–14627.

    https://doi.org/10.1073/pnas.0906334106

    • PubMed
    • Google Scholar
63. 1. Tong Y
    2. Yamaguchi H
    3. Giaime E
    4. Boyle S
    5. Kopan R
    6. Kelleher RJ III
    7. Shen J

    (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice

    PNAS 107:9879–9884.

    https://doi.org/10.1073/pnas.1004676107

    • Google Scholar
64. 1. Tong Y
    2. Giaime E
    3. Yamaguchi H
    4. Ichimura T
    5. Liu Y
    6. Si H
    7. Cai H
    8. Bonventre JV
    9. Shen J

    (2012) Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway

    Molecular Neurodegeneration 7:2.

    https://doi.org/10.1186/1750-1326-7-2

    • PubMed
    • Google Scholar
65. 1. Tong Y
    2. Shen J

    (2012) Genetic analysis of Parkinson’s disease-linked leucine-rich repeat kinase 2

    Biochemical Society Transactions 40:1042–1046.

    https://doi.org/10.1042/BST20120112

    • PubMed
    • Google Scholar
66. 1. Tsika E
    2. Kannan M
    3. Foo CS-Y
    4. Dikeman D
    5. Glauser L
    6. Gellhaar S
    7. Galter D
    8. Knott GW
    9. Dawson TM
    10. Dawson VL
    11. Moore DJ

    (2014) Conditional expression of Parkinson’s disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration

    Neurobiology of Disease 71:345–358.

    https://doi.org/10.1016/j.nbd.2014.08.027

    • PubMed
    • Google Scholar
67. 1. Ventruto V
    2. Sebastio L
    3. Festa B
    4. Farina L
    5. Caputo F

    (1975)

    Behavior of dermatoglyphics in leukemias

    Minerva Medica 66:2577–2581.

    • PubMed
    • Google Scholar
68. 1. Walton WH

    (1948) Feret‘s Statistical Diameter as a Measure of Particle Size

    Nature 162:329–330.

    https://doi.org/10.1038/162329b0

    • Google Scholar
69. 1. Watanabe H
    2. Shen J

    (2017) Dominant negative mechanism of Presenilin-1 mutations in FAD

    PNAS 114:12635–12637.

    https://doi.org/10.1073/pnas.1717180114

    • PubMed
    • Google Scholar
70. 1. West AB
    2. Moore DJ
    3. Biskup S
    4. Bugayenko A
    5. Smith WW
    6. Ross CA
    7. Dawson VL
    8. Dawson TM

    (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

    PNAS 102:16842–16847.

    https://doi.org/10.1073/pnas.0507360102

    • PubMed
    • Google Scholar
71. 1. Whiffin N
    2. Armean IM
    3. Kleinman A
    4. Marshall JL
    5. Minikel EV
    6. Goodrich JK
    7. Quaife NM
    8. Cole JB
    9. Wang Q
    10. Karczewski KJ
    11. Cummings BB
    12. Francioli L
    13. Laricchia K
    14. Guan A
    15. Alipanahi B
    16. Morrison P
    17. Baptista MAS
    18. Merchant KM
    19. Genome Aggregation Database Production Team
    20. Genome Aggregation Database Consortium
    21. Ware JS
    22. Havulinna AS
    23. Iliadou B
    24. Lee J-J
    25. Nadkarni GN
    26. Whiteman C
    27. 23andMe Research Team
    28. Daly M
    29. Esko T
    30. Hultman C
    31. Loos RJF
    32. Milani L
    33. Palotie A
    34. Pato C
    35. Pato M
    36. Saleheen D
    37. Sullivan PF
    38. Alföldi J
    39. Cannon P
    40. MacArthur DG

    (2020) The effect of LRRK2 loss-of-function variants in humans

    Nature Medicine 26:869–877.

    https://doi.org/10.1038/s41591-020-0893-5

    • PubMed
    • Google Scholar
72. 1. Xie C
    2. Pan J-L
    3. Wang W-W
    4. Zhang Y
    5. Zhang S
    6. Gan J
    7. Liu Z-G

    (2014) The association between the LRRK2 G2385R variant and the risk of Parkinson’s disease: a meta-analysis based on 23 case–control studies

    Neurological Sciences 35:1495–1504.

    https://doi.org/10.1007/s10072-014-1878-2

    • Google Scholar
73. 1. Xing W
    2. Liu J
    3. Cheng S
    4. Vogel P
    5. Mohan S
    6. Brommage R

    (2013) Targeted disruption of leucine-rich repeat kinase 1 but not leucine-rich repeat kinase 2 in mice causes severe osteopetrosis

    Journal of Bone and Mineral Research 28:1962–1974.

    https://doi.org/10.1002/jbmr.1935

    • PubMed
    • Google Scholar
74. 1. Xiong Y
    2. Neifert S
    3. Karuppagounder SS
    4. Stankowski JN
    5. Lee BD
    6. Grima JC
    7. Chen G
    8. Ko HS
    9. Lee Y
    10. Swing D
    11. Tessarollo L
    12. Dawson TM
    13. Dawson VL

    (2017) Overexpression of Parkinson’s Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology

    eNeuro 4:ENEURO.0004-17.2017.

    https://doi.org/10.1523/ENEURO.0004-17.2017

    • PubMed
    • Google Scholar
75. 1. Xiong Y
    2. Neifert S
    3. Karuppagounder SS
    4. Liu Q
    5. Stankowski JN
    6. Lee BD
    7. Ko HS
    8. Lee Y
    9. Grima JC
    10. Mao X
    11. Jiang H
    12. Kang S-U
    13. Swing DA
    14. Iacovitti L
    15. Tessarollo L
    16. Dawson TM
    17. Dawson VL

    (2018) Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice

    PNAS 115:1635–1640.

    https://doi.org/10.1073/pnas.1712648115

    • PubMed
    • Google Scholar
76. 1. Yamaguchi H
    2. Shen J

    (2013) Histological analysis of neurodegeneration in the mouse brain

    Methods in Molecular Biology 1004:91–113.

    https://doi.org/10.1007/978-1-62703-383-1_8

    • PubMed
    • Google Scholar
77. 1. Yu H
    2. Kessler J
    3. Shen J

    (2000)

    Heterogeneous populations of ES cells in the generation of a floxed Presenilin-1 allele

    Genesis 26:5–8.

    • PubMed
    • Google Scholar
78. 1. Yue M
    2. Hinkle KM
    3. Davies P
    4. Trushina E
    5. Fiesel FC
    6. Christenson TA
    7. Schroeder AS
    8. Zhang L
    9. Bowles E
    10. Behrouz B
    11. Lincoln SJ
    12. Beevers JE
    13. Milnerwood AJ
    14. Kurti A
    15. McLean PJ
    16. Fryer JD
    17. Springer W
    18. Dickson DW
    19. Farrer MJ
    20. Melrose HL

    (2015) Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice

    Neurobiology of Disease 78:172–195.

    https://doi.org/10.1016/j.nbd.2015.02.031

    • PubMed
    • Google Scholar
79. 1. Zabetian CP
    2. Samii A
    3. Mosley AD
    4. Roberts JW
    5. Leis BC
    6. Yearout D
    7. Raskind WH
    8. Griffith A

    (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations

    Neurology 65:741–744.

    https://doi.org/10.1212/01.wnl.0000172630.22804.73

    • PubMed
    • Google Scholar
80. 1. Zhang P
    2. Fan Y
    3. Ru H
    4. Wang L
    5. Magupalli VG
    6. Taylor SS
    7. Alessi DR
    8. Wu H

    (2019) Crystal structure of the WD40 domain dimer of LRRK2

    PNAS 116:1579–1584.

    https://doi.org/10.1073/pnas.1817889116

    • PubMed
    • Google Scholar
81. 1. Zhou R
    2. Yang G
    3. Shi Y

    (2017) Dominant negative effect of the loss-of-function γ-secretase mutants on the wild-type enzyme through heterooligomerization

    PNAS 114:12731–12736.

    https://doi.org/10.1073/pnas.1713605114

    • PubMed
    • Google Scholar
82. 1. Zimprich A
    2. Biskup S
    3. Leitner P
    4. Lichtner P
    5. Farrer M
    6. Lincoln S
    7. Kachergus J
    8. Hulihan M
    9. Uitti RJ
    10. Calne DB
    11. Stoessl AJ
    12. Pfeiffer RF
    13. Patenge N
    14. Carbajal IC
    15. Vieregge P
    16. Asmus F
    17. Müller-Myhsok B
    18. Dickson DW
    19. Meitinger T
    20. Strom TM
    21. Wszolek ZK
    22. Gasser T

    (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

    Neuron 44:601–607.

    https://doi.org/10.1016/j.neuron.2004.11.005

    • PubMed
    • Google Scholar

Author details

1. Jongkyun Kang

   Department of Neurology, Brigham and Women’s Hospital, Boston, United States

   Contribution

   Data curation, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing, Western analysis of deleted LRRK1 and LRRK2 mice as well as cDKO mice; quantitative histological and EM analyses of the SNpc, including independent quantification of TH+ neurons in the SNpc and quantification of TH+ terminals in the striatum

   Contributed equally with

   Guodong Huang

   Competing interests

   No competing interests declared

2. Guodong Huang

   Department of Neurology, Brigham and Women’s Hospital, Boston, United States

   Contribution

   Data curation, Investigation, Methodology, Writing – original draft, Northern analysis and RT-PCR followed by sequencing of floxed and deleted LRRK1 and LRRK2 mice; quantitative histological and EM analyses of the SNpc, including independent quantification of TH+ neurons in the SNpc and quantification of TH+ terminals in the striatum; independent behavioral validation

   Contributed equally with

   Jongkyun Kang

   Competing interests

   No competing interests declared

3. Long Ma

   Department of Neurology, Brigham and Women’s Hospital, Boston, United States

   Contribution

   Data curation, Investigation, Methodology, Generated the targeting vectors and performed ES cell experiments and Southern blotting for LRRK1

   Competing interests

   No competing interests declared

4. Youren Tong

   Department of Neurology, Brigham and Women’s Hospital, Boston, United States

   Contribution

   Data curation, Investigation, Methodology, Generated the targeting vectors and performed ES cell experiments and Southern blotting for LRRK2

   Competing interests

   No competing interests declared

5. Anu Shahapal

   Department of Neurology, Brigham and Women’s Hospital, Boston, United States

   Contribution

   Data curation, Investigation, Methodology, Writing – review and editing, Performed behavioral analysis

   Competing interests

   No competing interests declared

6. Phoenix Chen

   Department of Neurology, Brigham and Women’s Hospital, Boston, United States

   Contribution

   Data curation, Investigation, Methodology, Performed the GFP reporter analysis of DAT-Cre mice in the SNpc and the LC

   Competing interests

   No competing interests declared

7. Jie Shen

   1. Department of Neurology, Brigham and Women’s Hospital, Boston, United States
   2. Program in Neuroscience, Harvard Medical School, Boston, United States

   Contribution

   Conceptualization, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing

   For correspondence

   jshen@bwh.harvard.edu

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-1160-7118

• 681

  views

• 39

  downloads

• 0

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.